Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.

Journal of molecular neuroscience : MN - 1 Jun 2014

Kaplan Natalie, Vituri Aya, Korczyn Amos D, Cohen Oren S, Inzelberg Rivka, Yahalom Gilad, Kozlova Evgenia, Milgrom Roni, Laitman Yael, Friedman Eitan, Rosset Saharon, Hassin-Baer Sharon

Abstract excerpt

Levodopa-induced dyskinesias (LID) present a common but elusive complication of levodopa therapy in Parkinson's disease (PD). In order to identify genetic factors associated with LID, 352 (213 males) levodopa-treated Israeli PD patients were genotyped for 34 polymorphisms within three candidate g...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain-Derived Neurotrophic Factor
Share to Case-Control Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dopamine Plasma Membrane Transport Proteins

Share to Dyskinesia, Drug-Induced

Share to Levodopa

Share to Minisatellite Repeats

Share to Parkinson Disease

Share to Receptors, Dopamine D2

Source

Identifiers

PMID: 24633632
DOI: 10.1007/s12031-014-0276-9

Genes

BDNF
DRD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24633632-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.PMID 24633632Read ↗

Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s diseaseSemantic proximity Read ↗

Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.Semantic proximity Read ↗

Dopamine pathway and Parkinson’s risk variants are associated with levodopa-induced dyskinesiaSemantic proximity Read ↗

Association of dopamine receptor D3 polymorphism with Levodopa-induced Dyskinesia: A study on Parkinson's disease patients from India.Semantic proximity Read ↗

Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.Semantic proximity Read ↗

Pharmacogenetic profile and the development of the dyskinesia induced by levodopa-therapy in Parkinson's disease patients: a population-based cohort study.Semantic proximity Read ↗

BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.Semantic proximity Read ↗

Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson's disease.Semantic proximity Read ↗

Association of Parkinson disease age of onset with DRD2, DRD3 and GRIN2B polymorphisms.Semantic proximity Read ↗

The age at onset of LRRK2 p.Gly2019Ser Parkinson’s disease across ancestries and countries of originSemantic proximity Read ↗

Do tardive dyskinesia and L-dopa induced dyskinesia share common genetic risk factors? An exploratory study.Semantic proximity Read ↗

The influence of SLC6A3 and DRD2 polymorphisms on levodopa-therapy in patients with sporadic Parkinson's diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.